The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months
SHANGHAI, April 16, 2025 /PRNewswire/ -- The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results of ziresovir, a novel RSV-targeted antiviral drug developed by Shanghai Ark Biopharmaceutical Ltd. The article, titled "Efficacy and safety of ziresovir in hospitalised...
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study. IPAX-Linz is a single-arm Phase 2...
XellSmart’s Allogeneic iPSC-derived Cell Therapies for Parkinson’s Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials
SUZHOU, China, April 15, 2025 /PRNewswire/ -- In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submitted by XellSmart Biopharmaceutical (Suzhou) Co., Ltd. for its universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy for the treatment of Parkinson's disease (PD), the second most common neurodegenerative disease worldwide....
SECuRE trial update: First patient treated in the Phase II Cohort Expansion
HIGHLIGHTS The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee (SRC) after the successful completion of the Dose Escalation Phase to commence...
Pilatus Biosciences to Present Research on PLT012 at AACR 2025
Novel Immunometabolism Approach Targets Immune-Cold Solid Tumors DOVER, Del. and EPALINGES, Switzerland, April 15, 2025 /PRNewswire/ -- Pilatus Biosciences, pioneering biologics targeting metabolic checkpoints, will present new research on its lead candidate, PLT012, at the American Association for Cancer Research (AACR) 2025 Annual Meeting. The presentations will include an oral symposium by co-founder and Chair of the Scientific...
RevitaLash® Cosmetics Announces Road to $10 Million Goal in Support of Breast Cancer Initiatives
VENTURA, Calif., April 15, 2025 /PRNewswire/ -- RevitaLash® Cosmetics, globally recognized for its innovative lash, brow, and hair beautification products, is deepening its commitment to the fight against breast cancer with its new Road to $10 Million goal. In 2024, the company reached the milestone of $9 million in donations, investments, and...
Open nominations for the BIAL Award in Biomedicine 2025 with an increased amount to €350,000
Created to distinguish the most remarkable scientific discoveries in the biomedical field, this international award has been granted a growing reputation as a prelude to the Nobel Prize since it has distinguished in a former edition two authors subsequently honoured with the Nobel Prize in Medicine. PORTO, Portugal, April 15, 2025 /PRNewswire/ --...
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials
KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025....
Health In Tech Announces First Quarter 2025 Financial Results
Revenues increased 56% over the first quarter 2024 to $8.0 million, reflecting strong market demand Income before income taxes more than tripled to $0.7 million, up 257% over the first quarter 2024 Cash position remained strong at $7.6 million as of March 31, 2025 STUART, Fla., April 15, 2025 /PRNewswire/...
Covation Biomaterials Announces Launch of BioPTMEG at Chinaplas 2025
SHENZHEN, China, April 14, 2025 /PRNewswire/ -- Covation Biomaterials LLC ("CovationBio®"), a biomaterials company with advanced technology in the bio-based materials industry, proudly announces its newest innovation, CovationBio® bioPTMEG, the advanced, sustainable polytetramethylene ether glycol (PTMEG), delivering high performance with significantly lower environmental impact. BioPTMEG is a bio-based alternative to petroleum-based PTMEG, helping...
